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“Lipopolysaccharide inhibits ghrelin-excited neurons and reduces food intake via 
central nitric oxide signaling” 
Treatment with lipopolysaccharides (LPS) is a model of inflammatory disease-related 
anorexia. The neuromodulator nitric oxide (NO) mediates LPS anorexia as 
demonstrated by peripheral administration of 1400W, which specifically inhibits 
inducible NO synthase (iNOS). LPS induces iNOS expression in the hypothalamic 
arcuate nucleus (Arc), where NO inhibits orexigenic (ghrelin-excited) neurons. This 
study evaluates the hypothesis that central iNOS signaling mediates LPS anorexia. 
The effect of third intracerebroventricular (icv) injection of 1400W on LPS-induced 
anorexia was investigated. Furthermore, it was tested immunohistochemically 
whether LPS triggers the phosphorylation of the transcription factor STAT1, which 
contributes to iNOS gene expression. Central 1400W infusion reversed LPS anorexia 
and it attenuated LPS-dependent decreases in energy expenditure and respiratory 
quotient. Peripheral LPS treatment induced a significant pSTAT1 response in the Arc. 
In independent electrophysiological studies pharmacological iNOS blockade 
disinhibited orexigenic Arc neurons after in vivo or in vitro treatment with LPS. In 
conclusion, central NO signaling seems to contribute to LPS anorexia, possibly by 
inhibiting ghrelin-excited neurons via iNOS-dependent NO formation. Hence, 
pharmacological iNOS inhibition might be a therapeutic approach to treat disease 
related anorexia. 
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Abstract 
 
Lipopolysaccharide (LPS) induces anorexia and expression of inducible nitric oxide synthase 
(iNOS) in the hypothalamic arcuate nucleus (Arc). Peripheral administration of the iNOS 
inhibitor 1400W counteracts the anorectic effects of LPS. Here we investigated the role of 
central NO signaling in LPS anorexia. In electrophysiological studies we tested whether 
1400W counteracts the iNOS-dependent inhibition of Arc neurons triggered by in vivo or in 
vitro stimulation with LPS. We used the hormone ghrelin as a functional reference stimulus 
that is known to activate orexigenic Arc neurons. Further, we investigated whether in vitro 
LPS stimulation induces an iNOS-mediated formation of the second messenger cGMP. Since 
the STAT1 pathway contributes to the regulation of iNOS expression we investigated whether 
LPS treatment induces STAT1 phosphorylation in the Arc. Finally we tested the effect of 
intracerebroventricular injection of 1400W on LPS-induced anorexia. Superfusion with 
1400W (10-4 M) increased neuronal activity in 37% of neurons in Arc slices from LPS treated 
(100 µg/kg ip) but not from saline treated rats. Similarly, 1400W excited 45% of Arc neurons 
after in vitro stimulation with LPS (100 ng/ml). In both approaches, a considerable percentage 
of 1400W sensitive neurons were excited by ghrelin (10-8 M; 50% and 75%). In vitro 
stimulation with LPS induced cGMP formation in the Arc, which was blocked by co-
incubation with 1400W. LPS treatment elicited a pSTAT1 response in the Arc of mice. 
Central 1400W injection (4 µg/rat) attenuated LPS-induced anorexia and counteracted the 
LPS-dependent decrease in respiratory quotient and energy expenditure. In conclusion, the 
current findings substantiate a role of central iNOS dependent NO formation in LPS-induced 
effects on eating and energy homeostasis. A pharmacological blockade of NO formation 
might be a therapeutic approach to ameliorate disease-related anorexia. 
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Introduction 
 
Chronic anorexia is a deleterious consequence of inflammatory diseases, such as bacterial or 
parasitic infections, cancer, AIDS, kidney and heart failure, rheumatoid arthritis, chronic 
obstructive pulmonary disease (COPD) and others (Hart, 1988; Plata-Salaman, 1996). 
Sickness-related anorexia is a condition with negative impact on recovery and treatment 
success, with increased morbidity and mortality and with a decreased quality of life. The brain 
represents a major target for pro-inflammatory stimuli like pro-inflammatory cytokines that 
influence neuronal circuits controlling food intake and energy homeostasis. As part of these 
inflammatory processes the gaseous neuromodulator nitric oxide (NO) emerged as a possible 
mediator of sickness anorexia. Treatment with the bacterial endotoxin lipopolysaccharide 
(LPS), a major constituent of the cell wall of gram-negative bacteria, is a commonly used 
model for triggering an acute phase response that is associated with pronounced hypophagia 
(Abram et al., 2000; Langhans, 2007). Previous studies demonstrated an LPS-dependent 
expression of the inflammatory NO producing enzyme inducible nitric oxide synthase (iNOS) 
in the hypothalamic arcuate nucleus (Arc) (Wong et al., 1996) which is a key structure 
implicated in the control of energy homeostasis (Jansky et al., 1995; Woods et al., 1998). The 
artificial NO donor sodium nitroprusside (SNP) strongly inhibits Arc neurons that are 
activated by the orexigenic hormone ghrelin (Riediger et al., 2006). Moreover, LPS treatment 
attenuates fasting-induced activation of Arc neurons suggesting an interaction between hunger 
signals and LPS (Becskei et al., 2008). These findings lead us to hypothesize that NO might 
be implicated in the neuroinflammatory processes underlying LPS-induced anorexia.  
1400W is a specific and long acting iNOS inhibitor (Garvey et al., 1997). Peripheral 1400W 
injection attenuates LPS-induced hypophagia and associated disease symptoms such as 
inactivity, hyperthermia and reduced energy expenditure (Riediger et al., 2010). Although 
these studies support the concept that NO signaling contributes to LPS anorexia, it remained 
 9 
to be elucidated whether brain-intrinsic iNOS activity is important for this effect and whether 
LPS inhibits orexigenic Arc neurons via iNOS-dependent NO formation. In our current study 
we used electrophysiological, immunohistochemical and behavioral approaches to shed more 
light on the neuronal effects of NO in the context of sickness anorexia.  
Based on the assumption that a blockade of LPS-induced iNOS activity should result in 
increased neuronal activity of Arc neurons, we conducted in vivo and in vitro stimulations 
with LPS of rats and brain slices containing the Arc, respectively, and characterized the 
effects of the iNOS inhibitor 1400W on the electrical activity in the Arc. If our assumption 
that LPS inhibits orexigenic Arc neurons by induction of iNOS-dependent NO formation were 
correct, a blockade of endogenous iNOS activity after LPS stimulation should lead to 
increased neuronal activity, at least in a subpopulation of ghrelin-excited Arc neurons. There 
is in vitro and in vivo evidence that NPY neurons are directly activated by ghrelin (Dickson 
and Luckman, 1997; Kohno et al., 2003). Based on these studies it is justified to assume that 
NPY neurons are the major subpopulation of cells that are excited by ghrelin in the Arc. This 
is also supported by the fact that 94% Arc neurons expressing the ghrelin receptor are NPY 
positive (Willesen et al., 1999). In addition to its direct excitatory effect, ghrelin also 
indirectly inhibits putative pro-opiomelanocortin (POMC) neurons in the lateral Arc (Cowley 
et al., 2003; Riediger et al., 2003). In the present study, we recorded from the medial Arc, 
where ghrelin predominantly induces direct excitatory effects on Arc neurons that are directly 
inhibited by NO (Riediger et al., 2006; Riediger et al., 2003).  
As previously reported, prostaglandins might regulate iNOS gene expression (Chen et al., 
1999). Furthermore, prostaglandins contribute to the anorectic action of LPS (Langhans et al., 
1989; Lugarini et al., 2002). Therefore, we investigated the possible involvement of 
prostaglandins in the LPS/NO-dependent modulation of neuronal Arc activity. Using 
indomethacin to block cyclooxygenase (COX)-dependent prostaglandin synthesis we tested 
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whether prostaglandins are necessary for the presumed LPS-induced NO-dependent inhibition 
of Arc neurons. 
NO modulates neuronal activity and other biological actions by activating the soluble 
guanylate cyclase (sGC), which catalyzes the conversion of GTP to the second messenger 
cyclic GMP (Feil and Kleppisch, 2008; Schmidt et al., 1993). In previous immunohistological 
studies the NO donor sodium nitroprusside (SNP) elicited a cGMP response in the Arc 
(Riediger et al., 2006). Hence, an LPS/NO-mediated inhibition of Arc neurons is likely to be 
paralleled by an intracellular cGMP formation. This was tested under experimental in vitro 
conditions similar to the electrophysiological experiments. 1400W was used to confirm the 
possible involvement of iNOS in the LPS-mediated cGMP response.  
It was a further aim of this study to identify the possible transcriptional processes involved in 
LPS-induced iNOS expression in the Arc. The JAK-STAT pathway is an important 
intracellular signaling cascade regulating gene transcription in response to inflammatory 
stimuli (Lim and Cao, 2006). Among the different STAT isoforms particularly STAT1 seems 
to contribute to the activation of the iNOS promotor region (Guo et al., 2007). We therefore 
investigated the effect of peripheral LPS injection on STAT1 phosphorylation in the Arc. 
Finally, the ability of 1400W to cross the blood-brain barrier (Garvey et al., 1997) is an 
important pre-requisite for a potential therapeutic use of this drug and its derivatives. 
However, this characteristic makes it difficult to dissociate peripheral effects from central 
modes of action when 1400W is administered peripherally. In order to test whether central 
iNOS/NO signaling mediates sickness-related anorexia, we investigated the effect of third 
intracerebroventricular (icv) infusion of 1400W on the LPS-induced suppression of food 
intake.  
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Materials and methods 
 
Animals and housing conditions 
 
For the electrophysiological and behavioral studies, male adult Wistar rats (200-300 g) 
(Elevage Janvier, Le-Genest-St. Isle, France) were used. The animals were housed at 
controlled temperature (21 ± 1°C) and a 12-h/12-h artificial light cycle with ad libitum access 
to standard laboratory rat chow (890 25 W16, Provimi Kliba, AG, Kaiseraugst, Switzerland) 
and tap water. The behavioral and metabolic studies were conducted in an open-circuit 
indirect calorimetric system (AccuScan Instruments Inc.; Columbus, OH, USA). Rats were 
single-housed on a layer of wood shavings in Plexiglas cages (42x42x30 cm). Water bottles 
and food cups were placed on scales to measure water and food intake continuously. 
Powdered rodent chow (GLP 3433, Provimi Kliba, AG, Kaiseraugst, Switzerland) was used 
to avoid food hoarding and in order to precisely detect small amounts of eaten food.  
Male C57BL/6 mice bred in our local animal facility were used for the immunohistological 
detection of LPS-induced STAT1 signaling. Mice were group-housed in standard macrolon 
cages on a layer of wood shavings under a 12-h/12-h light-dark cycle with free access to 
rodent chow and water. All animals were handled and adapted to the experimental conditions 
before the onset of the experiments. The Veterinary Office of the Canton Zurich approved all 
experiments. 
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Electrophysiology studies 
  
The electrophysiological recording technique was described previously (Riediger et al., 2004; 
Riediger et al., 2006; Riediger et al., 2003; Traebert et al., 2002). Briefly, the rats were 
decapitated using a guillotine and their brains were quickly removed and superfused with ice-
cold artificial cerebrospinal fluid (aCSF) of the following composition (in mM): NaCl 124; 
KCl 5; NaH2PO4 1,2; MgSO4 1,3; CaCl2 1,2; NaHCO3 26; glucose 10; oxygenated and pH-
equilibrated with oxycarbon (95% O2, 5% CO2); pH 7,4; 290 mosm/kg. 700 µm thick coronal 
brain slices were cut at the mid-rostral level of the Arc using a vibratom (Leica VT1000S, 
Leica Microsystems, Germany). A rectangular 3x3 mm slice preparation containing the Arc 
was manually dissected under a dissection microscope and transferred to a temperature 
controlled (37°C) incubation chamber filled with constantly oxygenated aCSF. For 
recordings, the Arc preparations were then transferred to a temperature-controlled (37°C) 
recording chamber that was constantly perfused with oxygenated and pre-warmed aCSF at a 
rate of 1,6 ml/min. Extracellular single-unit recordings were obtained using self-made glass-
coated platinum-iridium electrodes. According to the neuroanatomical brain map (Paxinos 
and Watson, 2007), recordings were conducted in the medial arcuate nucleus (ArcM), in 
which the majority of neurons are excited by ghrelin (Riediger et al., 2003). 
In order to test whether LPS modulates the neuronal Arc activity via iNOS-dependent 
induction of NO, two different approaches were used. For the in vivo stimulation with LPS, 
rats received an intraperitoneal (ip) injection of 100 µg/kg LPS (from Escherichia coli, Sigma 
Aldrich, Switzerland) during the second half of the light phase and 4 hours before the animals 
were decapitated as described above. For the in vitro stimulation, brains from untreated rats 
were collected and prepared as described above. The slices were then incubated for 4 h in 240 
ml of aCSF in an incubation chamber containing 100 ng/ml of LPS. The sensitivity to the 
iNOS inhibitor 1400W (10-4 M; Calbiochem, Switzerland), the NO donor SNP (10-5 - 10-4 M; 
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Calbiochem, Switzerland) and rat ghrelin (10-8 M; Bachem, Switzerland) was tested by 
switching to an aCSF solution containing these substances. The aCSF used for the recordings 
did not contain LPS. 
In order to test whether the LPS/NO-induced effect on Arc activity depends on prostaglandin 
signaling, the COX inhibitor indomethacin (10-5 M) was co-incubated in vitro with LPS for 4 
h prior to electrophysiological recordings. At the end of the incubation period, the Arc 
preparations were transferred to the recording chamber and the sensitivity of Arc neurons to 
1400W, SNP and ghrelin was tested as described above. 
 
Immunohistological studies 
 
LPS induced iNOS-dependent cGMP formation in the Arc 
The effect of LPS on the intracellular formation of cGMP was investigated in Arc slices that 
were prepared under the same conditions as those in the electrophysiological studies. Arc 
sections were incubated for 4 h in aCSF containing LPS (100 ng/ml), LPS + 1400W (10-4 M), 
1400W or vehicle. In order to prevent the degradation of cGMP, the phosphodiesterase 
inhibitor 3-isobutyl-1-methylxanthine (10-5 M, IBMX, Sigma-Aldrich, Switzerland) was 
added after 2.5 h to the incubation medium. At the end of the total 4 h incubation period, Arc 
preparations were transferred to a 12-well plate filled with 2 ml of oxygenated aCSF. 
Incubations were terminated by adding 2 ml of ice-cold paraformaldehyde (PFA) solution 
(final concentration of 4% PFA in PBS, 1 h, 4°C). The fixative was replaced with ice-cold 
PFA solution containing 10% sucrose in phosphate buffered saline (PBS; 4°C, 2 h), followed 
by 10% sucrose in PBS (4°C, 30 min). 20 µm-thick frozen coronal sections were cut in a 
cryomicrotome (CM3050S, Leica Microsystems, Germany), thaw-mounted on microscopic 
glass slides (Superfrost Plus, Faust, Switzerland) and stored at -20°C. Sections were air-dried 
for 1 h at room temperature and subsequently rehydrated (3 x 5 min) with PBS containing 
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0.1% Triton® X-100 (PBST). The sections were then incubated with the primary antibody 
(anti-sheep cGMP antibody, 1:6000 in 0.3% PBST, kindly provided by Jan DeVente, 
University of Maastricht, Netherlands) for 24 h at 4°C. After washing with 0.1% PBST (3 x 
10 min) the sections were incubated with the secondary antibody at room temperature for 75 
min (Alexafluor 488 donkey-anti-sheep, Invitrogen, USA, 1:200 in 0.3% PBST). After final 
washing in 0.1% PBST (3 x 10 min) the slides were coverslipped with PBS/glycerol (1:1 v/v; 
Citifluor, Citifluor Ltd, UK). 
  
 
LPS induced STAT1 phosphorylation in the Arc 
Mice weighing approximately 35 g were subcutaneously (sc) injected with either LPS (40 
µg/mouse, dissolved in saline) or saline (100 µl/10g BW) at dark onset. The LPS dose was 
adopted from our previous immunohistochemical and behavioral studies (Becskei et al., 
2008). 4 hours after injection the mice were anesthetized by an injection of pentobarbital 
(pentobarbital sodium, 80 mg/kg, ip). The thorax was opened and the mice were transcardially 
perfused for 2 min with 0.9% NaCl followed by ice-cold PFA solution (2% in 0.1 M PB). 
Brains were removed and postfixed in ice-cold 2% PFA for 1 h and cryoprotected in 0.02 M 
potassium phosphate buffered saline (KPBS) containing 20% sucrose for the following 48 h 
at 4°C. Subsequently brains were snap-frozen at -20°C in hexane. Arc sections (20 µm) were 
cut in a cryomicrotome, thaw-mounted on microscopic glass slides and stored at -20°C until 
further processing. 
To detect pSTAT1 immunoreactivity the sections were air dried for 1 h and rehydrated in 0.02 
M KPBS. Antigen retrieval was achieved by 20 min incubation in 0.02 M KPBS 0.3% NaOH 
and 0.3% H2O2. Afterwards sections were incubated in 0.3% glycine (10 min) followed by 
0.03% sodium dodecyl sulfate (SDS, 10 min, both in 0.02 M KPBS). Unspecific binding was 
blocked by 20 min incubation in blocking solution (KPBS containing 4% donkey normal 
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serum (DNS), 0.4% Triton® X-100, 1% bovine serum albumin (BSA)). The primary antibody 
(rabbit anti-pSTAT1 (Tyr 701), 1:50, Santa Cruz Biotechnology) was applied for 48 h at 4°C 
in KPBS containing 1% DNS, 0.4% Triton® X-100 and 1% BSA. The secondary antibody 
(donkey anti-Rabbit Alexa 555 1:100, Invitrogen; diluted in KPBS containing 1% DNS and 
0.3% Triton® X-100) was applied for 2 h at room temperature. After final washing in 0.02 M 
KPBS the sections were coverslipped with citifluor.  
We also studied the effect of LPS on STAT1 phosphorylation in rats, but for unknown 
reasons we did not obtain a satisfactory immunohistochemical pSTAT1 signal at least under 
the current experimental conditions (not shown). Therefore, only the results obtained in mice 
are reported. 
 
Behavioral studies 
 
Effect of central iNOS inhibition on LPS-induced anorexia and metabolic parameters  
Rats weighing approximately 300 g were anesthetized with ketamin/xylazin (0,1 ml/100 g ip, 
0.66 mg xylazine and 6.66 mg ketamine/100 g BW) and placed in a stereotaxic device. 
Throughout surgery the rats were kept under isoflurane anesthesia.  
A 22-gauge guide cannula (C313G/Spc cut 9 mm, Plastics One, Roanoke, VA) was implanted 
into the third ventricle and anchored by dental cement and stainless screws. The coordinates 
for cannula placement were obtained from the rat brain atlas of Paxinos and Watson (Paxinos 
and Watson, 2007): anterioposterior: 2.2 mm posterior to bregma, lateral: ± 0.0 mm, 
dorsoventral: -7.5 mm). The animals were allowed 5-7 days of recovery after surgeries before 
the proper position of the guide cannula was confirmed by performing an angiotensin II 
stimulation test. Angiotensin II (10 ng/2 µl) was injected into the third ventricle with a 10 µl 
Hamilton syringe connected via polyethylene tubing to the injector that was inserted into the 
guide cannula. Cannula placement was considered successful if the animal consumed at least 
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5 ml of water during one hour after injection. Animals that did not fulfill this criterion were 
excluded from the study.  
Rats that passed the angiotensin II test were allocated to two groups. In each of these groups 
two treatments were conducted in a crossover design with a six-day interval between the 
trails. In the first group the rats received saline icv/saline ip or saline icv/LPS ip. In the second 
group, the rats were treated with 1400W icv/saline ip or 1400W icv/LPS ip. This paradigm 
was chosen to avoid repeated LPS treatments resulting in the development of LPS tolerance 
(Langhans et al., 1993; Riediger et al., 2010). LPS (100 µg/kg, ip) and 1400W (4 µg/rat in 2 
µl) were dissolved in sterile saline; treatments were conducted within 20 min before dark 
onset. 
Over 12 h, dark phase food intake and respiratory gas exchange was measured as described 
previously (Riediger et al., 2010) in order to calculate total energy expenditure (EE) and 
respiratory quotient (RQ). Food consumption was measured in 5 minutes intervals and saved 
on a computer. For EE and RQ measuring, ambient air was pumped through the cages via a 
manually adjustable flow controller (flow rate set to 2 l/min). Air entering and leaving each 
cage was monitored for its O2 and CO2 concentration. The cages were connected to two 
analyzers measuring O2/CO2 concentration of each cage for a period of 30 s in five minutes 
intervals, which allowed calculating EE and RQ using the manufacturer’s software 
(PhysioPlot Version 1.80, Integra ME Version 2.21; AccuScan Instruments Inc.). This 
calculation was based on the following equation: total energy expenditure (kcal/kg/h) = (3.9 x 
V (O2) + 1.1 x V (CO2))/1000; V (O2) and V (CO2); data were normalized for body weight. 
 
Statistical analysis  
 
From the constantly recorded rate meter counts, the mean spontaneous baseline activity of 
each single neuron was evaluated for 60 s before the stimulus (spontaneous activity). This 
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value was used to normalize changes in the firing rate expressed as absolute mean response 
change (Hz) and as percentage of mean response change. If both the absolute and the 
percentage of discharge rate changes during the response were larger than ±0.5 Hz and ±20%, 
respectively, the neuron was considered sensitive to the applied substance. Furthermore, the 
latency, the duration and the peak response (Hz) were also measured. The effect parameters of 
the electrophysiological responses were averaged and expressed as means ± standard errors 
(M±SE). Comparisons between different proportions of 1400W sensitive neurons observed 
under the different treatment conditions were made using the Fisher’s exact test. Mean 
spontaneous baseline activity of 1400W sensitive and insensitive neurons was compared 
using the Mann-Whitney-Wilcoxon test. 
For the quantification of the number of cGMP and pSTAT1 immunoreactive cells, a 
fluorescent microscope equipped with a digital camera system (AxioImager, Carl Zeiss AG) 
was used. The number of cGMP labeled cells of 5 corresponding Arc sections and the number 
of pSTAT1 labeled cells of 2-3 corresponding Arc sections from each animal were analyzed 
manually in blind fashion. From these values the mean number of positive cells per section 
was calculated for each animal. Statistical comparisons between treatment groups were 
performed using the one-way analysis of variance (ANOVA) for multiple groups (cGMP) and 
unpaired t-test for comparison between two groups (pSTAT1).  
For statistical evaluation of the behavioral and metabolic parameters the differences between 
the LPS treated groups relative to their respective control groups were calculated at each time 
point. These values were compared using parametric unpaired t-test. All data are presented as 
mean ± SEM, p < 0.05 was considered significant. 
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Results 
 
Electrophysiological studies 
 
In each of the electrophysiological approaches summarized below (in vitro or in vivo 
stimulation with LPS; in vitro studies involving LPS/indomethacin) separate recordings, Arc 
preparations and controls have been used. Therefore all of the pertinent data sets are 
independent. The mean amplitude of the action potentials for all recorded neurons was 120 
µV, which allowed an accurate discrimination from background noises.  
In line with the assumption that LPS induces iNOS-dependent NO signaling the Arc, the 
iNOS inhibitor 1400W induced excitatory effects in ghrelin-excited Arc neurons from LPS 
pre-treated rats (Fig. 1A). The responses started with a mean latency of 428 ± 117 s and 
seemed to be either irreversible or slowly reversible. Neurons that were excited by 1400W 
after LPS stimulation also often tended to show reduced spontaneous baseline activity 
compared to neurons from saline treated rats (Fig. 1A and Fig. 1B). During the stimulatory 
responses the mean absolute increase in firing was 1.5 ± 0.6 Hz from a mean spontaneous 
baseline activity of 0.7 ± 0.5 Hz (Table 1). In contrast to the excitatory effects of 1400W after 
LPS treatment, 1400W did not affect neuronal activity in Arc neurons from saline pre-treated 
control animals (Fig. 1B), except in one single neuron showing an excitatory response. To 
confirm NO sensitivity under control conditions, the NO donor SNP was superfused, which 
caused pronounced inhibitory responses in 86% of the tested cells (Fig. 1B). Neurons from 
LPS treated rats that increased their firing rate after 1400W displayed a significantly lower 
spontaneous baseline firing rate than neurons from LPS treated rats that were insensitive to 
1400W (Fig. 2). This indicates that the former neurons were tonically inhibited. 
In total, 37% (7/19) of all neurons tested from LPS treated rats were excited in response to 
1400W (Fig. 3A). One of the activated neurons showed a biphasic response with an excitatory 
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component at the beginning of the response followed by an inhibitory effect. In Arc neurons 
from control animals only 4% (1/23) of cells were activated by 1400W. The proportion of 
1400W sensitive neurons was significantly higher after LPS treatment than under control 
conditions. 
 
LPS not only induced inhibitory NO signaling in the Arc after in vivo stimulation but also 
under in vitro conditions. The outcome of the electrophysiological experiments conducted 
after in vitro incubation of Arc slices with LPS was similar to the in vivo observations 
described above. As shown by the representative recordings in Figure 4A, iNOS inhibition by 
1400W induced a marked increase in neuronal firing of Arc preparations that were incubated 
in LPS (for effect parameters see Table 1). This was not the case under control conditions of 
Arc slices pre-incubated with saline; this lack of responsiveness was not due to NO 
insensitivity as confirmed by superfusion of the NO donor SNP (Fig. 4B). 
While under control conditions only one out of 11 neurons (9%) increased its firing rate in 
response to 1400W, 45% (4/9) of the tested cells showed an increased activity after 1400W 
administration and one neuron (11%) was inhibited (Fig. 3B). This difference in the 
proportions of activated cells was significantly different. Similar to the experiments 
conducted after in vivo treatment with LPS, the majority of neurons showed inhibitory 
responses to SNP (66%) while one neuron was excited. Interestingly, the SNP-excited neuron 
was inhibited by 1400W. Although this type of response characteristic was exceptional, the 
opposing effects of iNOS blockade and exogenous NO administration were consistent. 
 
Similar to our previous electrophysiological studies from medial Arc neurons, ghrelin 
predominantly induced excitatory responses. 1400W/ghrelin co-sensitivity was tested in 16 
neurons after in vivo LPS treatment and in 9 cells after in vitro LPS stimulation. Excitatory 
ghrelin responses occurred in 44% and 56% of these recordings. Among the 1400W-excited 
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neurons 50% and 75%, respectively, were excited by ghrelin. Most of the remaining 1400W-
excited cells were insensitive to ghrelin because ghrelin-induced inhibitions are not frequently 
observed in the medial Arc of rats (around 11% of all recordings in the current experiments). 
 
In order to test whether prostaglandin signaling is required for the LPS/iNOS-dependent 
inhibition of Arc neurons, Arc slices were incubated in vitro with LPS in combination with or 
without the COX inhibitor indomethacin, which blocks prostaglandin synthesis. 
As shown by the representative recordings in Figure 5, 1400W induced excitatory responses 
after LPS incubation in the presence or absence of indomethacin indicating that prostaglandin 
signaling does not seem to be required for the LPS-dependent iNOS induction. Although the 
percentage of 1400W responsive neurons was slightly lower after COX blockade (33%; 6/18 
cells) the proportion of 1400W responsive cells was not significantly different when 
compared to the positive control conditions without indomethacin (45%; 5/11 cells) (Fig. 3C). 
The effect parameters for the responses induced by 1400W and the co-sensitivity to ghrelin 
were similar to the experiments involving LPS in vitro incubation described above (data not 
shown).  
  
Immunohistological studies 
 
LPS induced iNOS-dependent cGMP formation in the Arc 
To investigate whether LPS elicits NO-dependent cGMP formation in the Arc, slice 
preparations were incubated under comparable in vitro conditions as in the 
electrophysiological studies. As shown in Figure 6, LPS induced an increase in the number of 
cGMP immunoreactive cells in the Arc (Fig. 6A), while under control conditions low cGMP 
immunoreactivity was observed (Fig. 6B). Co-incubation with 1400W abolished the LPS-
dependent cGMP formation indicating mediation by iNOS (Fig. 6C). 1400W did not affect 
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the number of cGMP positive cells in the Arc when applied without LPS (Fig 6D). A 
significant LPS-induced cGMP response was only observed in the positive control conditions, 
but not in the presence of 1400W (Fig. 6E).  
  
LPS induced STAT1 phosphorylation in the Arc 
Peripheral injection of LPS triggered a pronounced STAT1 phosphorylation in the Arc of 
mice. Figure 7 shows representative immunostainings of Arc sections. The number of 
pSTAT1 immunoreactive cells was low in the saline treated control group. LPS treated mice 
showed a significantly increased number of pSTAT1 positive cells.  
 
Behavioral studies 
 
Effect of central iNOS inhibition on LPS-induced anorexia and metabolic parameters  
Compared to control conditions, LPS induced a strong anorectic response during the dark 
phase. In rats that received central 1400W infusion the LPS-mediated suppression of food 
intake was completely reversed during the first half of the dark phase and highly markedly 
attenuated during the rest of the activity phase (Fig. 8A). 1400W alone did not alter on food 
intake compared to control animals not receiving the iNOS inhibitor. The anorectic response 
to LPS was significantly attenuated in 1400W-treated animals for most time points during the 
dark phase when compared to the LPS-mediated feeding inhibition in rats without central 
iNOS blockade (Fig. 8B). 
Similar to the reversal of LPS-induced anorexia, 1400W also partly attenuated the gradual 
decrease in energy expenditure caused by LPS treatment. Although the LPS-dependent 
decrease in energy expenditure was clearly reduced in 1400W treated rats at all time points, 
statistical significance was only reached at 2 h after dark onset (Fig. 8C and 8D). Central 
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administration of 1400W alone did not seem to affect energy expenditure under the current 
experimental conditions. 
The LPS-mediated reduction in energy intake and expenditure was associated with a clear 
decline in the RQ reflecting increased fat metabolism (Fig. 8E and 8F). The RQ of 
1400W/saline treated rats closely paralleled the values of saline/saline treated controls while 
the LPS-induced decline in the RQ was markedly attenuated in LPS treated rats with 
pharmacologically inhibited central iNOS signaling; the 1400W-mediated blockade of the 
LPS-induced shift towards fat utilization was significant at most time points during the 
second half of the dark phase. During the first 6 h, the 1400W-induced attenuation of  LPS on 
RQ did not reach statistical significance. The fact that the absolute RQ value in LPS treated 
rats dropped below the physiological minimum value of 0.7 was probably related to a slight 
mismatch in the empirical calibration approach defining the RQ of a 24 h fasted rat as 0.7. 
However, this did not affect the measured change in RQ induced by LPS treatment relative to 
control conditions.  
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Discussion 
 
Electrophysiological studies 
 
The main aim of the electrophysiological studies was to show that LPS reduces the activity of 
Arc neurons by stimulating the iNOS-dependent NO production. The current study confirms 
this hypothesis and provides electrophysiological evidence that LPS stimulates endogenous 
iNOS dependent NO signaling in the Arc leading to a decreased activity of Arc neurons. This 
conclusion is based on the observation that the specific iNOS-inhibitor 1400W increased 
neuronal activity in the Arc after LPS-stimulation, while hardly any 1400W effect was seen 
under control conditions. After both, in vivo and in vitro LPS stimulation, a significant 
percentage of Arc neurons (37% and 45% respectively) were excited by 1400W indicating 
that LPS inhibits Arc neurons via induction of iNOS expression. Importantly, a there was a 
considerable co-sensitivity of 1400W-excited neurons to ghrelin (50% and 75%), which was 
similar to the previously reported co-sensitivity between leptin and ghrelin under comparable 
experimental conditions (Traebert et al., 2002). 
 
In previous immunohistochemical and electrophysiological studies the inhibitory effects of 
LPS and the nitric oxide donor SNP on Arc activity were demonstrated (Becskei et al., 2008; 
Riediger et al., 2010; Riediger et al., 2006). However, it had not been studied so far whether 
LPS inhibits Arc neurons via a stimulation of endogenous NO. Therefore, the current study 
extends the previous findings and supports the idea that NO might represent an endogenous 
anorectic signal in the Arc under inflammatory conditions. 
The majority of 1400W-mediated effects were irreversible or slowly reversible during the 
time of recording, which is consistent with the long-lasting effect of 1400W inhibition on 
enzymatic iNOS activity (Garvey et al., 1997). In addition to the indirect evidence that LPS 
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inhibits ghrelin-excited Arc neurons via iNOS-dependent NO release (disinhibitory effect of 
1400W), our findings also directly support this mechanism. Arc neurons from LPS treated 
rats that increased their activity in response to iNOS blockade showed a reduced baseline 
activity compared to 1400W insensitive neurons and also compared to the baseline activity of 
neurons from control rats that did not receive LPS. The fact that LPS treatment selectively 
toned down the activity of neurons that are 1400W responsive under these conditions strongly 
supports the hypothesis that LPS inhibits Arc neurons via NO formation. 
 
The observation that 1400W was almost ineffective under control conditions without LPS 
stimulation is consistent with low baseline iNOS activity in the Arc under unstimulated 
conditions. iNOS expression can be triggered by inflammatory stimuli (Kobayashi, 2010) and 
is supposed to be virtually absent in the brain under non pathological conditions (Wong et al., 
1996). A small percentage of the cells tested under control conditions were also sensitive to 
1400W. There are different possible explanations for this finding. On one hand there might be 
some basal expression of iNOS in the Arc that has not been detected with other methods. On 
the other hand it also cannot be excluded that some iNOS expression is triggered by the 
preparation of the Arc or during the subsequent storage of the brain slices in the incubation 
chambers. Irrespective of the underlying causes, this observation does not confound the main 
conclusion that LPS induces a NO-dependent inhibition of neuronal Arc activity as reflected 
by the significantly higher number of 1400W-excited neurons after LPS stimulation relative 
to control conditions.  
 
In the current study 50% and 75% of neurons responding to 1400W after in vivo and in vitro 
LPS stimulation, respectively, were also excited by ghrelin. This is an important finding, 
which might suggest that orexigenic (ghrelin-excited) Arc neurons belong to the target cells 
for LPS-induced NO signaling. Based on immunohistological and electrophysiological 
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evidence (Cowley et al., 2003; Traebert et al., 2002; Willesen et al., 1999) the vast majority of 
ghrelin-excited Arc neurons express NPY. Therefore, it is tempting to speculate that the 
inhibitory effect of NO on these neurons might decrease the release of the orexigenic 
neuropeptide NPY in other hypothalamic nuclei (e.g. lateral hypothalamic area (LHA), PVN). 
Studies showing a restoration of food intake after icv NPY administration in LPS treated 
animals are in line with this hypothesis (Edwards et al., 1999). 
Surprisingly, a low number of ghrelin-inhibited neurons (2/28) showed an increase in their 
activity in response to iNOS blockade after in vitro LPS stimulation. The functional relevance 
of this effect is unclear at present. The effect of NO on ghrelin-inhibited Arc neurons has not 
yet been specifically investigated. Although there is evidence that LPS seems to activate 
POMC/CART in the Arc (Sergeyev et al., 2001) the role of LPS-dependent nitric oxide 
signaling in these cells remains to be elucidated. 
In our studies we also observed some 1400W-responsive neurons that were insensitive to 
ghrelin. It cannot be excluded that these cells are also involved in the control of food intake. 
Based on the neurochemical and functional diversity of Arc neurons, it is reasonable to 
assume that inflammatory NO signaling might also affect other Arc-dependent effector 
pathways. The possible function of these cells remains to be identified in future studies.      
 
The electrophysiological results obtained after in vivo and in vitro stimulation with LPS are 
consistent. However, it is important to consider that in these two approaches, different 
inflammatory mechanisms might have contributed to the iNOS-mediated inhibition of Arc 
neurons. While after in vivo LPS injection a peripheral cytokine response is triggered (Jansky 
et al., 1995; Langhans, 2000), such an effect cannot occur when the Arc is isolated and 
stimulated under in vitro conditions. This does not necessarily exclude that the LPS/NO 
response in the Arc is independent of cytokine signaling because LPS may also induce a local 
cytokine production in the brain parenchyma or in structures of the blood-brain barrier (e.g. 
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endothelial cells) (Konsman et al., 2004). It was beyond the scope of this study to dissociate 
direct effects of LPS on NO signaling in the Arc from indirect cytokine-mediated effects. 
Nevertheless, it can be concluded that a local action of LPS either in structures of the BBB or 
within the brain tissue itself is sufficient to elicit a NO dependent modulation of neuronal Arc 
activity.   
 
Similar to cytokines, prostaglandins play an important role in the mediation of LPS anorexia 
(Lugarini et al., 2002; Pecchi et al., 2009). Therefore we investigated whether a blockade of 
the prostaglandin-producing enzyme COX interferes with the LPS/NO-mediated modulation 
of neuronal Arc activity. COX blockade did not prevent the excitatory effect of 1400W on 
Arc neurons after LPS incubation. In fact the number of 1400W sensitive cells was similar 
with or without COX inhibition. This suggests that prostaglandins are not required for the 
LPS-dependent induction of NO signaling in the Arc under our test conditions but these 
results do not rule out that COX/prostaglandin signaling modulates Arc activity independently 
of NO. Although the current experiments were not designed to test this, a similar approach 
could be used to investigate whether superfusion of indomethacin leads to a change in 
neuronal activity in the Arc after in vivo or in vitro stimulation with LPS. 
 
Immunohistological studies 
   
LPS induces iNOS-dependent cGMP formation in the Arc 
We hypothesized that the LPS-dependent induction of NO in the Arc is mediated via cGMP 
signaling. The current results support this assumption because LPS led to an increase in the 
number of cGMP positive cells in the Arc. This effect was mediated by iNOS because 1400W 
completely blocked the LPS-mediated cGMP formation. Notably, the cGMP response in the 
Arc was comparable to previous studies demonstrating a cGMP formation in the Arc after 
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incubation with the NO donor SNP (Riediger et al., 2006). Similar to these studies cGMP 
positive neurons were clearly present in the medial subregion of the Arc corresponding to the 
localization of the recording site in the electrophysiological experiments. Previous 
electrophysiological studies demonstrated that the membrane-permeating analog 8-Br-cGMP 
mimics the inhibitory effect of NO on ghrelin-excited Arc neurons (Riediger et al., 2006). 
Moreover, the inhibitory action of the NO donor SNP was blocked by the sGC-inhibitor 
ODQ. Together these findings strongly suggest that the intracellular second messenger cGMP 
mediates the LPS/NO-dependent Arc inhibition.  
 
 
LPS induces STAT1 phosphorylation in the Arc 
We and others previously demonstrated a time-dependent STAT3 phosphorylation in the Arc 
after LPS injection (Gautron et al., 2002; Riediger et al., 2010; Rummel et al., 2005). Notably, 
this effect did not occur in rats that were made LPS tolerant by repeated LPS treatments 
(Langhans et al., 1993). Hence, the loss of LPS anorexia appears to be associated with the 
absence of LPS-induced STAT3 phosphorylation (Riediger et al., 2010). Our current study is 
the first to demonstrate that LPS also triggers a pSTAT1 response in the Arc. For 
experimental reasons we only report an LPS-induced STAT1 phosphorylation in mice. Based 
on the similarity of the general neurophysiology of the Arc in rats and mice there is no 
indication that the inflammatory neuromechanisms that were investigated differ 
fundamentally between these species. We did not attempt to block the pSTAT1 response with 
1400W because pSTAT1 is a known regulator of iNOS gene expression and therefore 
proximal to iNOS in the LPS-STAT-iNOS signaling cascade. Hence, at least within the 
framework of our hypotheses, we would not expect any effect of 1400W on the LPS-induced 
STAT1 phosphorylation. There is cumulating evidence that iNOS expression is linked to 
STAT1 signaling. The iNOS promoter region is flanked by cytokine responsive DNA motifs. 
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One of these binds STAT1 and upregulates iNOS gene transcription (Guo et al., 2007). A 
STAT1-mediated induction of iNOS expression by cytokines and LPS has been demonstrated 
in different cell systems including astroglial and epithelial cells (Dell'Albani et al., 2001; 
Kleinert et al., 1998; Stempelj et al., 2007; Tedeschi et al., 2003). It therefore appears likely 
that LPS-induced STAT1 phosphorylation occurs in these cell types in the Arc similar to what 
has been demonstrated for STAT3 (Kim et al., 2002; Rummel et al., 2006). It might be 
interesting to determine the phenotype of the pSTAT1 positive cells. It has to be noted, 
however, that NO acts as a diffusible neuromodulator in a paracrine manner. Therefore, it can 
reach and act on neurons within the Arc irrespective of the cell types that release NO in 
response to LPS.  
In contrast to a comparably high basal abundance of pSTAT3 immunoreactive cells in the Arc 
of rats and mice (Becskei et al., 2010; Riediger et al., 2010), the number of pSTAT1 positive 
cells was much lower under control conditions. Hence, physiological non-inflammatory 
stimuli inducing basal STAT3 phosphorylation do not seem to evoke pSTAT1 under the same 
experimental conditions. Whether pSTAT1 signaling in the Arc is more specific to 
inflammatory stimuli than pSTAT3 has not yet been elucidated. Similarly, it is possible that 
the profiles of targets genes regulated by pSTAT3 and pSTAT1 are different. While genetic 
disruption of STAT signaling bears experimental problems (lethality, altered immune status, 
etc.) (Takeda and Akira, 2000) a pharmacological blockade of STAT signaling might be an 
experimental approach to confirm the involvement of pSTAT signaling in iNOS gene 
expression in the Arc and in LPS anorexia. 
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Behavioral studies 
 
Effect of central iNOS inhibition on LPS-induced anorexia and metabolic parameters  
Proceeding from our previous studies showing an attenuation of LPS anorexia after peripheral 
1400W treatment (Riediger et al., 2010) we now provide evidence that central iNOS/NO 
signaling is involved in sickness anorexia. Central infusion of 1400W blocked the suppressive 
effect of LPS on food intake and attenuated the LPS-induced decreases in RQ and energy 
expenditure. Under our test conditions and using our doses (4 µg/rat), the anti-anorectic effect 
of 1400W appeared to be even stronger than after peripheral administration, because LPS 
anorexia was completely blocked at least during the first half of the activity phase. It is 
conceivable that the attenuation of LPS anorexia after peripheral 1400W administration is 
probably due to a central effect because 1400W crosses the blood-brain barrier (Garvey et al., 
1997).  
Our current electrophysiological and immunohistological studies point to a possible 
involvement of the Arc in disease-related anorexia. However, other hypothalamic structures 
might also be involved. The paraventricular nucleus (PVN) shows a high iNOS expression 
during inflammation (Wong et al., 1996) and is therefore also a potential brain area where 
inflammatory NO signaling might affect food intake. Future studies using site-specific 
injections of 1400W could help to confirm the importance of single brain areas in NO-
dependent anorexia.  
To our knowledge there are no published studies investigating the effect of centrally 
administered specific iNOS-inhibitors on LPS-induced anorexia. In several previous studies 
the effect of unspecific NOS-inhibitors on food intake was tested under non-pathological 
conditions. Central applications of the unspecific NOS-inhibitors NG-nitro-L-arginine methyl 
ester (L-NAME) or NG-nitro-L-arginine lead to a decrease in food intake (De Luca et al., 
1995; Squadrito et al., 1993). These findings are not necessarily contradictory to our results 
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because NO has a well-established function in the control of food intake under non-
inflammatory physiological conditions (Morley et al., 2011). Various studies have shown that 
the actions of orexigenic neuropeptides and hormones including orexin-A, NPY and ghrelin 
depend at least in part on nitric oxide (Farr et al., 2005; Gaskin et al., 2003; Morley et al., 
1999). Even if the exact mechanism and the involved brain structures mediating these NO 
actions remain to be identified, these effects are thought to be primarily mediated by the 
constitutive NOS isoforms. iNOS is supposed to be absent in the brain under these non-
inflammatory conditions (Wong et al., 1996). Therefore, a non-specific NOS inhibition that 
includes a blockade of nNOS and eNOS may lead to a decrease in food intake under non-
pathological conditions (De Luca et al., 1995; Squadrito et al., 1993). The fact that we did not 
observe an effect caused by 1400W alone but only reversal of LPS anorexia supports the 
specificity of this iNOS inhibitor. 
Similar to our recent studies (Riediger et al., 2010) the anorectic effect of LPS was paralleled 
by a decrease in energy expenditure and RQ. These responses were also partly attenuated by 
central iNOS blockade. For experimental reasons we did not try to reproduce the telemetric 
measurements of physical activity and body temperature that we conducted in our recent 
study (Riediger et al., 2010). Although we cannot exclude direct effects of LPS on energy 
expenditure, the drop in metabolic rate may at least partly be secondary to a decrease in 
locomotor activity and a decrease in the specific dynamic action of food intake on energy 
expenditure. The LPS-induced decrease in energy intake caused a drop in RQ reflecting 
increased lipid oxidation. The attenuation of this response by 1400W is in line with the 
beneficial effect of iNOS inhibition on the general energy status because it suggests a 
preservation of internal energy stores. Notably, our data are consistent with previous studies 
reporting a decreased RQ value after LPS treatment under comparable experimental 
conditions (Hollis et al., 2011; Hollis et al., 2010). To our knowledge there are no published 
studies testing the effect of LPS on RQ values in food deprived rats. In principle, such studies 
 31 
would exclude the possible influence of treatment-induced changes in energy intake on RQ 
values. However, food restriction or food deprivation per se introduces confounding factors 
that limit the interpretation of RQ values under such conditions. The RQ of food-deprived rats 
decreases to low values, which might make it difficult to detect a treatment-induced decline in 
RQ. Furthermore, food deprivation increases food-seeking behavior at least in healthy 
animals, which has an impact on metabolism that is difficult to control for in LPS treated rats. 
Within the framework of our objectives, we did not intend to exclude any determinants 
contributing to changes in RQ under physiological ad libitum feeding conditions. Therefore, 
and because of the experimental limitations described above we did not include studies using 
food-deprived animals.   
 
Overall, a pharmacological iNOS inhibition might be a possible approach to treat disease-
related anorexia under chronic conditions either as a single drug treatment or in combination 
with other anti-anorectic agents. Particularly our current demonstration that inflammatory NO 
signaling inhibits the target cells for the orexigenic hormone ghrelin might be of crucial 
importance in this context. Earlier studies pointed to a possible use of ghrelin or ghrelin 
mimetics as an anti-anorectic agent for the treatment of different forms of sickness anorexia 
(DeBoer et al., 2007; Hanada et al., 2003; Hataya et al., 2003; Nagaya et al., 2005; Neary et 
al., 2004; Strassburg et al., 2008). The synthetic ghrelin analog (BIM-28131) exerted positive 
effects on food intake and body weight in healthy and in tumor-bearing rats (Langhans, 2000; 
Strassburg et al., 2008). Moreover it improved lean body mass in a rat model of chronic 
kidney disease, which is associated with increased inflammatory cytokines and cachectic 
weight loss (Deboer et al., 2008). In human studies the safety, tolerability and 
pharmacokinetics of ghrelin as a possible anti-anorectic/anti-cachectic drug has been 
evaluated. Ghrelin treatment is well tolerated and safe in cancer patients, but it did not 
significantly improve food intake and body weight relative to placebo treatment (Strasser et 
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al., 2008). However, the negative efficacy data of the human studies using ghrelin treatment 
have to be interpreted with caution due to variables that might need to be better controlled. 
Other clinical phase I and phase II trials confirmed a positive effect of an oral ghrelin mimetic 
(RC-1291) on food intake and body weight in both healthy volunteers and cancer patients 
(Garcia et al., 2007; Garcia and Polvino, 2007).  
Although the general outcome of existing preclinical and clinical studies evaluating the 
treatment with ghrelin or ghrelin mimetics are promising, cancer anorexia/cachexia seems to 
be associated with decreased ghrelin responsiveness which might limit the efficacy ghrelin 
dependant therapeutic approaches. Under most but not all tumor-induced cachectic conditions 
ghrelin levels are elevated, but this increase in the circulating hormone concentration of active 
ghrelin is not reflected in an increase in energy intake that may be expected (Garcia et al., 
2005). Therefore it has been postulated that tumor anorexia might be associated with a partial 
decrease in ghrelin responsiveness, which appears to be in line with the reduced effectiveness 
of centrally administered ghrelin to increase food intake in tumor-bearing rats compared to 
non-tumor-bearing controls (Wisse et al., 2001). The mechanism underlying this decreased 
ghrelin responsiveness is unknown. Our previous and novel findings showing a NO-
dependent inhibition of ghrelin-sensitive neurons under inflammatory conditions suggest a 
causal relationship between NO and decreased ghrelin responsiveness. Therefore, a 
combination treatment with ghrelin receptor agonists and iNOS inhibition is likely to result in 
improved treatment outcome.  
 
In summary our study further substantiates the concept that neuroinflammatory NO signaling 
plays a crucial role in the mediation of sickness-related anorexia. Orexigenic Arc neurons are 
inhibited by endogenous iNOS-dependent NO formation in response to LPS-induced 
inflammation. Moreover, LPS triggers intracellular pathways in the Arc that are involved in 
iNOS gene transcription (STAT1) and in NO signaling (cGMP). iNOS inhibition might be 
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pharmacological approach to treat disease-related anorexia or to improve the treatment 
success of other therapeutic strategies. 
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Figure legends: 
 
Figure 1: Effect of iNOS blockade on the electrical activity of ghrelin-excited Arc neurons 
from an LPS treated (100 µg/kg) (A) and a saline treated control rat (B). The iNOS inhibitor 
1400W increased the firing rate after LPS treatment but not under control conditions. NO 
responsiveness of the 1400W insensitive neuron was confirmed by the inhibitory effect NO 
donor SNP. Firing rate was increased by ghrelin. 
 
Figure 2: Mean baseline activity before 1400W administration of 1400W-insensitive and 
1400W-excited Arc neurons after in vivo stimulation with LPS. Neurons that increased their 
firing rate in response to pharmacological iNOS inhibition displayed a significantly lower 
baseline spontaneous activity than 1400W unresponsive Arc neurons (Mann-Whitney-
Wilcoxon Test, p < 0.05). The dashed-line represents the mean spontaneous baseline activity 
of in vivo saline pre-treated neurons. 
 
Figure 3: Responsiveness of Arc neurons to the iNOS inhibitor 1400W after saline or LPS 
treatment (A) and after in vitro incubation of Arc slices without or with LPS (B). The number 
of 1400W-excited neurons was significantly increased after in vivo or in vitro incubation with 
LPS (Fisher Exact Test, * p < 0.05, ** p < 0.01). A blockade of prostaglandin synthesis by 
co-incubation with the COX inhibitor indomethacin did not change the excitatory effect of 
1400W on Arc neurons after in vitro stimulation with LPS (C).  
 
Figure 4: Effect of iNOS blockade on the electrical activity of ghrelin-excited Arc neurons 
after 4 h LPS incubation (100 ng/ml) (A) or control incubation without LPS (B). The iNOS 
inhibitor 1400W increased the firing rate after LPS incubation but not under control 
conditions. NO responsiveness was confirmed by the NO donor SNP. 
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Figure 5: Responsiveness of Arc neurons to the iNOS inhibitor 1400W after 4 h LPS 
incubation (100 ng/ml) in the presence (A) or absence (B) of indomethacin (10-5 M). 1400W 
induces excitatory responses in both cases. NO responsiveness was confirmed by the NO 
donor SNP. 
 
Figure 6: Effect of iNOS blockade on LPS-induced cGMP formation in the Arc. 
Representative immunostainings of the Arc showing the effect of 4 h in vitro incubation with 
LPS (100 ng/ml) on cGMP formation in the absence (A, B) or presence (C, D) of the iNOS 
inhibitor 1400W (10-4 M). Scale bar = 100 µm. (E) Quantitative analysis 4 h in vitro 
incubation with LPS (100 ng/ml) significantly increased the number of cGMP 
immunoreactive Arc neurons. This response was blocked by the iNOS inhibitor 1400W (10-4 
M). Different letters indicate statistical differences between groups (one-way ANOVA F 
(3,12) = 12.77, p = 0.0005; Newman-Keuls Multiple Comparison Test p < 0.01). 
 
Figure 7:  Representative immunostainings of the Arc of mice showing LPS-induced pSTAT1 
response. Scale bar = 200 µm. Peripheral LPS treatment (40 µg/mouse) significantly 
increased the number of pSTAT1 immunoreactive cells in the Arc of mice 4h after injection 
(unpaired t-test; p < 0.05). 
 
Figure 8: Effect of central iNOS inhibition on LPS-induced reduction in dark phase food 
intake (A+B), energy expenditure (C+D) and RQ (E+F). When compared to control 
conditions the LPS-dependent reductions in these parameters were significantly attenuated by 
central infusion of 1400W. (t-test; * p < 0.05, ** p < 0.01, n = 3-4). See text for explanation 
concerning absolute RQ values. 
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Tables and figures 
 
Table 1 
 
 In vivo LPS stimulation In vitro LPS stimulation 
Parameters 
M ± SEM 
(n = 6) 
M ± SEM 
(n = 4) 
   
Mean spontaneous activity [s] 0.7 ± 0.5 1.6 ± 0.9 
Mean latency [s] 428 ± 117 189 ± 68 
Absolute response [Hz] 1.5 ± 0.6 1.8 ± 0.5 
Absolute peak response [Hz] 2.7 ± 0.9 3.2 ± 0.5 
Mean response duration [s] 928 ± 169 1727 ± 64 
 
 
Table 1: Effect parameters of the excitatory responses induced by 1400W (10-4 M, n = 6 and 
n = 4) in vivo and in vitro respectively.  
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